Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera,…
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…
Looking At Johnson & Johnson’s Recent Unusual Options Activity
A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson &…
Reported Late Wednesday March 08, Johnson & Johnson Announces Pricing Of $7.75B Of Senior Notes Issued By Kenvue Inc.
Johnson & Johnson (NYSE:JNJ) today announced that Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an
‘Johnson & Johnson Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy Of Macitentan And Tadalafil Significantly Improves Pulmonary Hemodynamics Versus Monotherapy In Patients With Pulmonary Arterial Hypertension’
https://johnsonandjohnson.gcs-web.com/static-files/3137d414-8b4a-432d-bee1-16af33aa8233
Johnson & Johnson Unit Janssen Announced New VOYAGER PAD Analysis Confirms Consistent Benefit Of XARELTO Plus Aspirin Following Lower Extremity Revascularization
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following
Johnson & Johnson Unit Janssen Announced New STELARA Long-Term Data Support Its Established Safety Profile In Inflammatory Bowel Disease And Durable Efficacy In Ulcerative Colitis
he Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn's disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extensi
JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility
Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…
Jim Cramer Says He’s Known Novavax Is ‘Worthless’ For ‘Very Long Time,’ Trashes Company For Being Too ‘Promotional’
Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue.
Jim Cramer isn't surprised.